共 126 条
[1]
Younes A(2016)Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and Brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Lancet Oncol 17 1283-1294
[2]
Santoro A(2020)Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers 6 38-228
[3]
Shipp M(2017)PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD Blood 130 221-3175
[4]
Zinzani PL(2010)Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 3167-515
[5]
Timmerman JM(2020)Moving towards personalized treatments of immune-related adverse events Nat Rev Clin Oncol 17 504-515
[6]
Ansell S(2018)Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight 3 510-270
[7]
Ramos-Casals M(2020)Monitoring PD-1-blocking antibodies bound to T cells derived from a drop of peripheral blood J Vis Exp 108 955-1439
[8]
Brahmer JR(2018)Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma Int J Hematol 8 253-1026
[9]
Callahan MK(2020)Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer J Immunother Cancer 14 1428-1427
[10]
Flores-Chávez A(2022)Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review Cancers (Basel) 17 1021-3277